Patients with colon cancer who still have cancer cells in their blood after surgery may improve their survival odds with ...

Recent research indicates that colon cancer patients with circulating tumor DNA post-surgery may improve their survival likelihood with daily celecoxib use. Celecoxib, a COX-2 inhibitor, significantly ...

SANG W. LEE PROCTOLOGY Clinical Professor; Chief, Colon and Rectal Surgery Keck Medicine of USC Dr. Sang Lee is one of the nation’s leading experts in ...

Dwyane Wade reflected on having a cancerous tumor removed from his kidney as well as 40 percent of the organ itself after ...

About 61% of patients with stage I or II dMMR colon cancer achieved a pathologic complete response after a single cycle of neoadjuvant pembrolizumab, new data revealed.

The methylation of plasma cell-free DNA (cfDNA) has emerged as a valuable diagnostic and prognostic biomarker in various cancers including colorectal cancer (CRC). Currently, there are no biomarkers ...

Agenus (AGEN) announced publication in the Journal of Clinical Oncology showcasing data from its study of botensilimab in combination with ...

Taking 160 milligrams of aspirin a day cuts the risk of cancer recurrence in half among colon cancer patients with a mutation ...

New data from two studies presented at ASCO GI 2025 demonstrated that ctDNA testing could predict recurrence risk in ...

The blood test was 81% accurate in detecting colon cancer among people who have the disease, researchers reported at the 2025 ...

A recent analysis from a randomized clinical trial conducted by researchers at the Dana-Farber Brigham Cancer Center ...